Evidence map›Paper›PMID 38439165›Full record

ReviewESC heart failure2024

Epidemiology and risk factors for hyperkalaemia in heart failure.

Diederick E Grobbee, Gerasimos Filippatos, Nihar R Desai, Andrew J S Coats, Fausto Pinto, Giuseppe M C Rosano, John G F Cleland, Jennifer Kammerer, Antonio Ramirez de Arellano

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 7 countries.

Diederick E GrobbeeJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0003-4472-4468
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
Nihar R DesaiCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
Andrew J S CoatsHeart Research Institute, Sydney, Australia.
Fausto PintoDepartment of Cardiology, Centro Hospitalar Universitário Lisboa Norte, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Giuseppe M C RosanoClinical Academic Group Cardiovascular, St George's University Hospital London, UK, Cardiology, San Raffaele Cassino, Italy.
John G F ClelandBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Jennifer KammererCSL Vifor, Redwood City, CA, USA.
Antonio Ramirez de ArellanoCSL Vifor, HEOR, Glattbrugg, Switzerland.
British Heart Foundation · GBNational and Kapodistrian University of Athens · GRSt George's Hospital · GBThe Heart Research Institute · AUUniversity Medical Center Utrecht · NLUniversity of Lisbon · PTVifor Pharma (Switzerland) · CHVifor Pharma (United States) · USYale New Haven Hospital · US

Funding

Vifor Pharma
6 · The paper itself

Abstract

Patients with heart failure (HF), particularly those with impaired renal function receiving renin-angiotensin-aldosterone system inhibitors (RAASis), are at risk of hyperkalaemia; when hyperkalaemia is severe, this can have serious clinical consequences. The incidence, prevalence, and risk factors for hyperkalaemia reported in randomized trials of RAASis may not reflect clinical practice due to exclusion of patients with elevated serum potassium (sK

Indexed as

Heart FailureHyperkalemiaGlobal HealthHumansIncidencePotassiumPrevalenceRisk FactorsPotassiumEpidemiologyHeart failureHyperkalaemiaRenin–angiotensin–aldosterone system inhibitorsRisk factors

Identifiers

PMID38439165
PMCPMC11287317
OpenAlexW4392466262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.